Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.

Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, Levin MD, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Niemann CU, Kater AP

Open source

DOI: 10.1200/jco.22.02283
Published: 2023 Jul 20
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.22.02283,
  title = {Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.},
  author = {Munir T and Moreno C and Owen C and Follows G and Benjamini O and Janssens A and Levin MD and Osterborg A and Robak T and Simkovic M and Stevens D and Voloshin S and Vorobyev V and Yagci M and Ysebaert L and Qi K and Qi Q and Parisi L and Srinivasan S and Schuier N and Baeten K and Howes A and Caces DB and Niemann CU and Kater AP},
  year = {2023},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco.22.02283},
  url = {https://doi.org/10.1200/jco.22.02283}
}

RIS

TY  - JOUR
TI  - Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
AU  - Munir T
AU  - Moreno C
AU  - Owen C
AU  - Follows G
AU  - Benjamini O
AU  - Janssens A
AU  - Levin MD
AU  - Osterborg A
AU  - Robak T
AU  - Simkovic M
AU  - Stevens D
AU  - Voloshin S
AU  - Vorobyev V
AU  - Yagci M
AU  - Ysebaert L
AU  - Qi K
AU  - Qi Q
AU  - Parisi L
AU  - Srinivasan S
AU  - Schuier N
AU  - Baeten K
AU  - Howes A
AU  - Caces DB
AU  - Niemann CU
AU  - Kater AP
PY  - 2023
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco.22.02283
UR  - https://doi.org/10.1200/jco.22.02283
ER  -

APA

T, M., C, M., C, O., G, F., O, B., A, J., MD, L., A, O., T, R., M, S., D, S., S, V., V, V., M, Y., L, Y., K, Q., Q, Q., L, P., S, S., N, S., K, B., A, H., DB, C., CU, N., & AP, K. (2023). Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco.22.02283

Source records

pubmed · retrieved 2026-09-27T09:26:42.220Z